ClinicalTrials.gg
CompletedNCT06412237Updated Oct 7, 2026

An Exploratory Study of a Wearable Robotic Hand Orthosis

An interventional study of RELab tenoexo in Stroke, sponsored by Tan Tock Seng Hospital. Completed at 1 site in Singapore. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Tan Tock Seng Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Now CompletedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Stroke by Tan Tock Seng Hospital — 3 open to participants now, 6 under way, none of them phase 3. Stroke · Tan Tock Seng Hospital.

Enrollment
19th of 20
8 · median 17
Started
2024
with 6 others
No phase
19 of 29
2 open now
Registered
25th of 29
by date

Among the 29 studies in Stroke by Tan Tock Seng Hospital, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2024, is one of 19 with no phase, and was the 25th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 29 studies in Stroke by Tan Tock Seng Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stroke by Tan Tock Seng Hospital, or all of them as a file.
02

Study summary

Upper limb deficits usually remain in 75% of the stroke survivors despite completing full rehabilitation. This is due to lack of effectiveness of rehabilitation and the degree of support and resources available.

In this study, the investigators plan to study the use of assistive technologies in chronic stroke survivors.

Read the detailed description

Assistive technologies have shown promising results in immediate improvement in functional abilities.

RELab tenoexo is a fully wearable and portable robotic hand orthoses (RHO) used for functional training. Its design support end users with functional hand opening and closing and can be applied in therapy exercises or during functional activities. While prior research demonstrated its effectiveness for spinal cord injury, it hasn't been tailored for multi-ethnic stroke populations.

This study aims to determine the feasibility and extent to which the RELab tenoexo can complement therapy training in clinic and further be used as both a training and assistive device in the home environment. In addition, it also aims to investigate the amount of upper limb usage before, during and after the training period.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Hand exoskeleton robot
  • Robotic hand orthosis
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with first ever clinical stroke (ischaemic or haemorrhagic) with hemiplegic motor deficit(s) due to stroke as diagnosed by CT or MRI.
  • Post stroke of at least 6 months with stable neurological status.
  • Age 21 to 80 years of age.
  • Hemiplegic pattern and shoulder abduction MRC motor power > 2/5 and elbow extension >2/5
  • Has a stable home abode and a carer/NOK to assist with donning of device and supervise home based exercise
  • MOCA > or equal to 22/30
  • Able to give and sign at research site.
  • Able to speak English

Exclusion criteria

Exclusion Criteria:

  • Non-stroke related causes of arm motor impairment.
  • Has unstable or terminal medical conditions which may affect participation (e.g.: unresolved sepsis, postural hypotension, end stage renal failure, cancer, retroviral disease, on therapy) or anticipated of \<1 year due to or neurodegenerative disorder.
  • Local factors which may be worsened by intensive arm therapy: spasticity of Modified Ashworth Scale grades 3-4, skin wounds, shoulder pain Pain Scale >5/10, active/non-united fractures or arthritis or fixed joint/tissue flexion contractures of shoulder, elbow, wrist or fingers incompatible with tenoexo interface.
  • Patient with severe cognitive, perceptual (include hemi-neglect), and/or emotional-behavioural issues that preclude participation.
  • Experiencing moderate to severe levels of pain (Numerical Vertical Pain Scale > 5).
  • Is pregnant or breast feeding. Neither the tenoexo nor the IMUs have been tested to evaluate the usage with pregnant and/or breast feeding mothers. Further, due to the length of the study, pregnancy may make it difficult to follow the study schedule.
  • Have a pacemaker. Magnets are used throughout the system.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    RELab tenoexo

    3 weeks in clinic training (9 training sessions, two clinical assessment and 2 usability evaluations) followed by 2 weeks home training (1-hour daily training and to the extent participants desire). Lastly 1-month follow up clinical assessment and IMU data collection.

    Device: RELab tenoexo

Interventions

  • DeviceRELab tenoexo

    The RELab tenoexo is a fully wearable and portable RHO developed at the Rehabilitation Engineering Laboratory (RELab) at ETH Zurich.

06

What researchers measure

Primary outcomes

  1. Action Research Arm Test (ARAT) Score

    Functional and dexterity score in the affected arm evaluated using 19 tests of motor function across 4 subsets; minimum score = 0, maximum score = 57, with higher score indicating better function.

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

Secondary outcomes

  1. Fugl-Meyer Motor Assessment (FMA) scale

    Change in Fugl Meyer Motor Assessment score in the affected arm, minimum: 0, maximum: 66 with higher scores indicating greater levels of mobility function

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

  2. Grip Strength (kg)

    Measured by Digital hand-held Dynamometer (mean of 3 readings) for both hands

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

  3. Hr-QOL scales using SS-QOL (Stroke specific Quality of Life scale)

    Quality of life scale specific to stroke patients, minimum 49, maximum 245; with higher scores indicating better function.

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

  4. EQ-5D-5L scale

    Standardized measure of health-related quality of life using a 5 level scale (no problem, slight problems, moderate problems, severe problems, unable to)

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

  5. Self-efficacy outcomes by UPSET (upper limb self-efficacy test)

    Questionnaire to measure self-efficacy in various tasks after stroke

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

  6. System Usability Scale (SUS)

    To assess the overall usability of the tenoexo (effectiveness, efficiency, satisfaction), scaled from 1 (Strongly disagree) to 5 (Strongly Agree)

    Time frame: Week 3 (mid in-clinic training), 4 (end of in-clinic training), 8 (end of home training)

  7. Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST)

    To evaluate user satisfaction with assistive technology, scaled from 1 (Not satisfied at all) to 5 (Very satisfied)

    Time frame: Week 3 (mid in-clinic training), 4 (end of in-clinic training), 8 (end of home training)

Other outcomes

  1. Modified Ashworth Scale (MAS)

    Measures the level of spasticity at the elbow and finger flexors of proximal interphalangeal joint regions; scored from "0 to 4" with "4" indicating affected part is more spastic in flexion/extension.

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

  2. Visual Analogue Scale (self-reported pain score)

    Unidimensional measure of pain intensity; "0" being no pain and "10" being worst pain.

    Time frame: Week 2 (baseline), 4 (end of in-clinic training) ,8 (end of home training) ,12 (follow-up assessment)

07

Study locations

1 site
  • Tan Tock Seng Hospital
    Singapore, Singapore, Singapore
08

References and documents

Publications

  • Tanczak N, Plunkett TK, Lin S, Kuenzler L, Lau M, Kuah WKC, Ng CY, Gassert R, Chua K, Lambercy O. Feasibility of post-stroke hand rehabilitation supported by a soft robotic hand orthosis in-clinic and at-home. J Neuroeng Rehabil. 2025 Aug 21;22(1):183. doi: 10.1186/s12984-025-01717-6. PubMed 40842028 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jan 2026, 19 months.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 19 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
May 14, 2024
StartActual
Jun 1, 2024
Primary completionActual
Jan 27, 2026
CompletionActual
Jan 27, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 7, 2026
Sites
1 site added, 1 site removed
Show site
  • Tan Tock Seng Hospital · Singapore, Singapore
Show 1 removed
  • Tan Tock Seng Hospital · Singapore, Singapore
Oct 7, 2026
Enrollment
20 (estimated)→8 (actual)
Oct 7, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40842028 ↗
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40842028 ↗
    1 site added, 1 site removed
    Show site
    • Tan Tock Seng Hospital · Singapore, Singapore
    Show 1 removed
    • Tan Tock Seng Hospital · Singapore, Singapore
    Enrollment 20 (estimated)→8 (actual)
    + 5 other changes: index terms, verification date, date precision, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06412237
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Jun 1, 2024
Primary completion
Jan 27, 2026
Completion
Jan 27, 2026
Last update
Oct 7, 2026

Study contacts

Tegan Plunkett
principal investigator · Tan Tock Seng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion